BeyondSpring Inc.
Close on Oct 19, 2026
- Market cap
- $21.09M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-0.04 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | – | – | – |
Press releases
Announcements BeyondSpring filed with the SEC
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
Material agreement · Other events · EX-99.1 to Form 8-K
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
BeyondSpring Reports 2025 Year-End Financial Results
Results of operations · EX-99.1 to Form 8-K
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SEED Therapeutics Completes $30 Million Series A-3 Financing
Material agreement · Other events · EX-99.1 to Form 8-K
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
Results of operations · EX-99.1 to Form 8-K
Unaudited Pro Forma Condensed Consolidated Financial Information
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity
Material agreement · Other events · EX-99.1 to Form 8-K
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
EX-99.1 to Form 6-K
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
EX-99.1 to Form 6-K
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
EX-99.1 to Form 6-K
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K